Harvard Apparatus Regenerative Technology Inc. (HRGN)

Market Cap	26.71M -0.3%
Revenue (ttm)	982.00K +44.6%
Net Income	-6.68M
EPS	-0.39
Shares Out	17.58M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	1.519
Previous Close	1.519
Day's Range	1.519 - 1.519
52-Week Range	0.960 - 2.220
Beta	-0.35
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 9, 2026

About HRGN

Harvard Apparatus Regenerative Technology Inc., a clinical-stage biotechnology company, focuses on developing regenerative-medicine treatments for disorders of the gastro-intestinal system and other organs resulting from cancer, trauma, or birth defects. The company’s lead product candidate is Cellspan Esophageal Implant for the treatment of severe esophageal disease. It’s pipeline includes organ-regeneration technology for the repair or replacement of diseased or damaged organs; and product candidates to treat conditions of the esophagus, incl...

• Industry: Packaged Foods
• Sector: Consumer Staples
• Founded: 2009
• Employees: 8
• Stock Exchange: OTCMKTS
• Ticker Symbol: HRGN

Financial Performance

In 2025, HRGN's revenue was $704,000, an increase of 63.72% compared to the previous year's $430,000. Losses were -$6.87 million, -11.16% less than in 2024.

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Aug 25, 2026

Data Sources Report a data error